MALAT1 and non-small cell lung carcinoma: Thus, it would be reasonable to analyze MALAT1 in plasma of NSCLC patients instead of the cellular fraction, because the presence of MALAT1 in plasma might be a direct effect of the tumor, e.g., release of lncRNA-containing extracellular vesicles[39].